Why Boots Is Heading to Canadian Hands: The £6.7 Billion Deal, Explained

Why Boots Is Heading to Canadian Hands: The £6.7 Billion Deal, Explained
Why Boots Is Heading to Canadian Hands: The £6.7 Billion Deal, Explained
AhemBeauty · Business of Beauty

On October 7, a Canadian family holding company agreed to buy one of the best-known names on the British high street. The price was $8.9 billion, or about £6.7 billion, with debt included. The buyer was Wittington Investments, the holding company of the Weston family, who already run Canada’s largest pharmacy chain through Loblaw. The seller was a New York private equity firm that had owned Boots for little more than a year.

That timeline is the first thing worth sitting with. A company founded in 1849 changed hands twice in roughly twelve months, and the second buyer is an ocean away from the first. For anyone who buys No7 serum, picks up a prescription, or just wanders into Boots for a Meal Deal, the obvious question is simple: why does this keep happening, and does it change anything on the shelf?

We went through the deal announcements, the filed accounts, analyst commentary and a range of customer and pharmacist feedback available online. Some of it is reassuring. Some of it is awkward. Here is the full picture, written for readers in the US, the UK and Canada, because all three markets touch this story differently.

The deal in plain numbers

Wittington will acquire Boots’ retail and pharmacy operations in the UK and Ireland, Boots Opticians, the No7 Beauty Company, and Boots’ Thailand and franchise businesses. That is roughly 1,800 stores and more than 50,000 colleagues.

Toronto-based Fairfax Financial is partnering on the purchase. The ownership arrangement deserves a closer look: Fairfax has committed to provide up to approximately $2.3 billion towards the purchase price and is expected to own 50% of Boots’ equity following completion. Wittington, however, will retain operational control. Galen Weston, Wittington’s chairman, will become chairman of Boots.

This is an important distinction. The Weston family will lead the business operationally, while Fairfax will be an equal equity partner. The acquisition is therefore a Canadian investment partnership rather than a straightforward purchase by Loblaw or Shoppers Drug Mart.

Completion is expected in the first quarter of 2027, subject to regulatory approval and customary closing conditions. At the time of writing, the sale had not closed, so everything below describes the proposed transaction rather than a completed change of ownership.

Two things were left out of the package. Sycamore Partners and the Pessina family are keeping Farmacias Benavides in Mexico and Alliance Healthcare Deutschland in Germany. And the American Walgreens business, the original parent, was never part of this sale at all.

The seller was not offloading a distressed asset. Boots had just reported rising revenue and statutory profit. The more interesting question is how much of that profit represents sustainable improvement.

Why Sycamore wanted out so quickly

Go back to 2025, when Sycamore Partners bought Walgreens Boots Alliance in a deal valued at up to $23.7 billion including debt. The firm then split the group into five standalone businesses: Walgreens, The Boots Group, VillageMD, CareCentrix and Shields Health Solutions. The logic was that the combined group was worth less than its parts.

Once Boots stood alone, the exit options were a London listing as soon as 2027, or a sale. Reporting through the spring and summer suggested a private sale was winning. Australia’s Sigma Healthcare held talks and then withdrew over the summer. The Westons stayed in, and in August they reportedly lowered an earlier offer, which Sycamore rejected.

The final price is telling. Early reports floated around $10 billion. The signed deal is $8.9 billion including debt. The financing structure is also important: Fairfax has committed up to approximately $2.3 billion, while the wider transaction includes acquisition financing and assumed debt.

A quick exit, then, but not at the top of the range first discussed.

There is a human detail too. Alex Baldock, the former Currys chief executive, started as Boots CEO on September 2. Five weeks later, he had a buyer and an incoming chairman to work with.

Why the Westons wanted Boots

On paper, the fit is almost uncomfortably neat. Boots and Shoppers Drug Mart are cousins in everything but ownership: both are national, pharmacy-led health and beauty chains with deep loyalty programmes and a strong grip on skincare. Loblaw bought Shoppers in 2014 in a deal announced at around C$12.4 billion, and today Shoppers runs more than 1,300 pharmacy locations across Canada. Boots has about 1,800 stores across its wider operations.

A retail strategist quoted in Canadian coverage pointed out the price comparison: the Westons are paying less in headline terms for a larger store estate than they paid for Shoppers a decade ago. That comparison is imperfect, because currency, interest rates and the state of UK pharmacy have all changed, but it explains the family’s appetite.

The Westons also know Britain. Their Canadian arm, through Wittington, owned Selfridges from 2003 until it was sold to Thailand’s Central Group in a roughly £4 billion deal. A separate British branch of the family controls Associated British Foods, which owns Primark, and Fortnum & Mason. This is not a first date with UK retail.

What the family says it wants is patient capital. Galen Weston has described a "meaningful opportunity" to make a great business better through stable, long-term ownership and further capital investment. That is the opposite of a private equity pitch, which by design has an exit date attached. Wittington says its plans include upgrading stores, improving the online experience and expanding healthcare services.

There is one more number worth pulling out. At Shoppers Drug Mart, pharmacy and healthcare services grew 7.5% in Loblaw’s most recent second quarter, against just 1.3% growth in the front of the store. Boots is running a similar pattern in the UK, where weight-loss treatments and pharmacy services are growing faster than ordinary shelf sales. The Westons are not just buying shelves. They are buying a place where health services and beauty browsing share a single trip.

Two clarifications keep the story honest. First, Boots is being acquired by Wittington in partnership with Fairfax, not by Loblaw or Shoppers Drug Mart, and no combination of the two chains has been announced. Second, anyone hoping for a quick "Boots comes to Canada" headline should wait: No7 already sells through Shoppers, and no change to that arrangement has been announced.

Shoppers Drug Mart storefront in Canada, part of the Weston family's Canadian pharmacy retail business
Shoppers Drug Mart provides a useful comparison for the Weston family’s pharmacy-led retail strategy in Canada.

A short history of a very long-lived chemist

Boots began in 1849 when John Boot, a devout Methodist and herbalist, opened a small shop on Goose Gate in Nottingham selling herbal remedies. Medical treatment was expensive then, and a cheap remedy from a local shop was a real service to working families.

Historic Nottingham streetscape representing the origins of Boots in 1849
Boots began as a small herbalist shop in Nottingham in 1849.

John died in 1860, when his son Jesse was only ten. Jesse’s mother Mary kept the business going, and Jesse took over fully in 1877, opened his first chemist’s shop that year, and turned a corner herbalist into a national chain. The company was incorporated in 1883 and became Boots Pure Drug Company in 1888.

A detail that matters here: in 1920 Jesse Boot sold the company to the American United Drug Company. Economic conditions in North America deteriorated, and in 1933 Boots was sold back into British hands. Overseas ownership is not new for this brand.

Through the twentieth century the chain became the default British chemist. Boots developed ibuprofen in the 1960s and added opticians, photography and a big beauty offer. In 2006 it merged with the wholesaler Alliance UniChem to form Alliance Boots, which went private in 2007.

Walgreens bought a 45% stake in 2012 for $6.7 billion and completed the full merger on December 31, 2014, creating Walgreens Boots Alliance. In 2025 Sycamore bought that group, and in October 2026 Boots changed hands again through the announced agreement with Wittington and Fairfax.

What has stayed constant through all of it is the shop, and the trust people place in the name above the door.

Profit, loss and what the accounts actually say

This is the section where headlines and accounts part ways, so it is worth going slowly.

Financial accounts and business analysis illustrating Boots revenue and operating profit
Boots’ reported results need to be read alongside exceptional accounting adjustments.

Boots UK’s accounts for the year to August 31, 2025, filed at Companies House in June, show revenue up 3.2% to £7.545 billion. Gross profit rose by £90 million to £2.771 billion. Comparable-store retail sales climbed 5.8%, and Boots.com grew 18.3%. Post-tax profit was £261 million, up about £50 million on the previous year. Several outlets reported pre-tax profit of £337 million, a 25% jump, and that is the number most coverage led with.

Now the caveat. According to an analysis of the same accounts, Boots UK Limited’s operating profit of £355 million included a £115 million net impairment reversal booked after Sycamore’s takeover. That reversal reflected changes in the assessed value of assets, including pharmacy licences, store improvements and leased assets.

There is another accounting item that matters when comparing the two years. The previous financial year included a £219 million pension-related past-service credit, alongside a £187 million impairment charge.

These exceptional items need to be considered together rather than looking at the £115 million reversal in isolation.

A simplified adjusted comparison looks like this:

Financial measure 2024 2025
Reported operating profit £274m £355m
Pension credit removed -£219m —
Impairment charge added back +£187m —
Impairment reversal removed — -£115m
Illustrative adjusted operating profit £242m £240m

This is an analytical adjustment using the identified exceptional items, not an alternative statutory profit measure published by Boots.

The comparison suggests that underlying operating profit was broadly flat, at approximately £240 million in both years. In other